Enrique Vega, Azalea Vision - Healthtech for Vision Disorders | LSI Europe '22

Transcription

Enrique Vega  0:08  

Good morning. I'm Enrique Vega, co founder and CEO of Azalea Vision. There are many patients that are suffering from different symptoms. These patients are coming from different conditions but the symptoms are the same. Let me put you one example patients with high risk disorders for example, they suffer from lack of depth of field. It's the same symptom that patients with presbyopia are suffering. The patients also with various disorders might suffer from photophobia which is also a common symptom software by patients with albinism, or patients with chronic migraine, dry eye syndrome or traumatic brain injury. Or the patients for example, the Patients with Traumatic eye injury might suffer from glare glare or loss on a starburst. Actually, this is the same these are the same symptoms that the patients post LASIK with some errors are suffering or cataract operations or multifocal multifocal IOL implantation some of these devices, they create some side effects, which are related with glare analysis. So, completely different patients are suffering from the same conditions. And physicians are not finding the right solution for these patients. This is exactly what we are developing in our family our vision we are developing an iris bionic Iris, but it's not inside the body, it's in our contact lens, the bionic Iris is actually made of nanotechnology. As you can see here in the bottom left, there is an NFC antenna some chips connected with let's say the brain the intelligence a battery, that will last for the whole day of operations. This is produced on a wafer level. And then it's thermal formed and embedded inside a contact lens. So what we will have actually is a series of rings that we can address independently and programmed and customize for each patient. First because the patient might have different needs, but also the patient will have the control to change the therapy as they move from a room like this with the light in front of me or going to a walk in the park. We also are developing smart case that the patient will use to charge the device during the night clean the device because his eye contact lens and eventually program the device the video is not rendering very good. So this this product will be let's say customize by the patient as as they move forward. Just an example of patient with Nvidia and Z max. Simulation you see here in the left what a patient would see with any leader would see these patients we then add our patients where the iris is not working at all it's an extreme patient, and you're seeing the right what the patient would see with our platform. And actually the fact that you can see here is as you close the iris, the vision the visual quality, let's say will increase. So that is exactly what we will be able to do to customize in this Iris to each patient. If you think about which are their solutions today there is no solution that matches what these kinds of patient needs either you implant an iris like the mortar or human optics or optics now there are some iOS also that they have a ring of course this is a fixed ring inside the eye. And then there is also these lenses from Johnson and Johnson Acuvue which are a great product but there are no Iris effect there is no rings is just let's say a song glass that takes one to two minutes to become dark and one on two minutes to become transparent. So in our case we will not require any kind of surgery, we can command the pinhole effects the patients will keep the control of the therapy if needed with a smartphone. And as it is a contact lens we will be able also to correct refractive errors like myopia or astigmatism in terms of of our roadmap of patients, we will start if I can start with the low hanging fruit where the patients with Aniridia where the iris is completely dysfunctional patients also with presbyopia we are going to develop the solution initially inside an scleral contact lens to move after to soft contact lens. We will start some ideas studies somewhere in 2024 with these Aniridia and presbyopia patients and at that moment we will develop and include the same electronics but inside a soft contact lens because our platform is completely bendable. This can be included in a soft contact lens. And then at that moment without the novel submission We are also discussing with FDA to get our breakthrough device submission, then in that case, we will be able to use our de novo submission as a predicate for the next market expansion. We have We are three founders. Andres Vasquez, Peter Malina, myself we have already very good investors like I make expand Elia sense, you know, but and we have been collaborating with different physicians and different doctors, we are spinoff from IMEC and University of Kent, and we have already since July, we started the company last July, we have 10 people working on the different specialties, and a bunch of physicians and technicians that are helping us to put in place our company. So as some of we are developing a smart bionic Iris to alleviate the symptoms related with light with light sensitivity. The total addressable market that we estimate is close to 6 billion per year, as the company was incubated in IMEC. And the University of Ghent for five years there's a lot of steps already the risk since July we are now working on on the development of the product and on the wafer production so that we will have reduced CoCs since the beginning. And we have a strong IP portfolio that we let's say got from IMEC annual grant and we are developing further these, these IP portfolio. The series A which happens last year, it was 6 million from our investors. We also got two millions from grants from Belgium institutions. And we are now thinking about how to put in place the Clinical Strategy round which will be Series B, and it will be between 15 and 20 million. That's all I have. Thank you